Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

orate Executive Team.   "Our focus now is to continue to advance Amigal for Fabry disease and it is our hope to deliver a first-in-class, oral medicine to the thousands of people worldwide living with this devastating rare disease."

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics said, "The completion of this agreement with GSK is a transformational event for Amicus. It provides a strong validation of the potential for Amigal to become an important new treatment option for people living with Fabry disease and for our pharmacological chaperone technology broadly.  GSK has extremely impressive global clinical, regulatory and commercial expertise and a strong commitment to the development of treatments for rare diseases. We look forward to working in close partnership with them."  Crowley continued, "With this key strategic alliance with GSK and the added financial strength it provides, Amicus is now uniquely positioned to build shareholder value through our expertise in rare disease drug development."  

About Amigal™ (migalastat HCl) for the Treatment of Fabry DiseaseMigalastat HCl is an investigational treatment for Fabry disease and has the potential to be the first in a new class of oral, small molecule medicines called pharmacological chaperones.  It is designed to selectively bind to and stabilize the target enzyme alpha-galactosidase A (alpha-Gal A), which facilitates proper trafficking of the enzyme to the lysosomes, where it is needed to break down the target substrate globotriaosylceramide (GL-3).

Results from Phase 2 studies of migalastat HCl, which has orphan designation in both the US and EU, demonstrated that in subjects identified as responders to migalastat HCl treatment resulted in increased levels of alpha-Gal A, reduced levels of GL-3 as measured in renal interstitial capillary cells from kidney biopsies and in urine, and a potential positive impact on renal functio
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015   NineSigma the leading innovation partner ... in estimated overall revenue growth and anticipates the creation of ... Open Innovation Incentive (OII). In 2013, the ... grant of over $2 million to accelerate adoption of open ... Million and $1 Billion in revenues. To date over 45 ...
(Date:8/27/2015)... 27, 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ... at the Morgan Stanley Global Healthcare Conference on September ... are invited to listen to the live discussion via ... directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded ... after the conclusion of the live event and accessible ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015  Generex Biotechnology ... issuance of a white paper on the status of ... The white paper was presented to the August 19, ... James H. Anderson, Jr. , MD, the Company,s ... online on the Generex website. The white ...
Breaking Medicine Technology:State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... Reportlinker.com announces that a new market research ... Global Kidney Stone Management ... http://www.reportlinker.com/p0611035/Global-Kidney-Stone-Management-Devices-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_D This report analyzes ... Devices in US$ Million by the following ...
... RMD ) announced today that it will be presenting ... Conference at the Grand Hyatt in New York City on September ... Grand Hyatt in New York City on September 20, 2011; ... in Phoenix, AZ on November 9, 2011; Piper Jaffray Healthcare ...
Cached Medicine Technology:Global Kidney Stone Management Devices Industry 2Global Kidney Stone Management Devices Industry 3Global Kidney Stone Management Devices Industry 4Global Kidney Stone Management Devices Industry 5Global Kidney Stone Management Devices Industry 6Global Kidney Stone Management Devices Industry 7Global Kidney Stone Management Devices Industry 8Global Kidney Stone Management Devices Industry 9Global Kidney Stone Management Devices Industry 10Global Kidney Stone Management Devices Industry 11ResMed Inc. to Present at Upcoming Conferences 2
(Date:8/27/2015)... Mesa, AZ (PRWEB) , ... August 27, 2015 , ... ... out of more than 2,100 applicants worldwide, selected based on academic rigor, leadership and ... the attainment of a baccalaureate degree. , Sypher will receive a medallion and a ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article ... Association have released new guidelines to educate doctors and patients on the best practices ... particular guidelines came in 2007, so the new version is taking into account nearly ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, at the Adams County ... of the “Music With A Mission” benefit concert. For the past two years, “Music ... the underfunded school districts of Mendon and neighboring town, Quincy, IL. Organized in part ...
(Date:8/27/2015)... ... 2015 , ... StayWell, a leading provider of patient education ... ready and available to all clients. All Krames Patient Education content has been ... targeted and return a more comprehensive data set of content than the ICD-9 ...
(Date:8/27/2015)... ... August 27, 2015 , ... Banc Intranets recently entered into ... will enable both Johnson City, Tenn.-based firms to work synergistically to promote similar products ... product that caters to organizations in the financial, commercial and services sectors. The software, ...
Breaking Medicine News(10 mins):Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4
... international team of pathologists studied an initial 4,000 prostate cancer ... into the natural progression of the disease and how it ... British Journal of Cancer , could be used to develop ... of prostate cancer. Globally, prostate cancer is ...
... people worldwide, researchers say , WEDNESDAY, Sept. 23 (HealthDay ... only one injection produced promising results in animals, U.S. ... to undergo six shots over 28 days -- five ... rabies immunoglobulin. , The new replication-deficient rabies virus vaccine ...
... ... Training from American TeleCare, Inc. to Integrate Telehealth into the Education and Clinical Practice ... ... (ATI), Inc. announced that the Allied Health Department, University of Hawaii-Maui Community College (UH-Maui ...
... BERLIN, Sept. 23 Bayer HealthCare Pharmaceuticals ... today announced the full results from their first collaborative ... Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic ... advanced breast cancer. The data were presented at ...
... ... has been officially recognized by the City of Chicago. In honor of this day, The ... local celebrations. , ... (PRWEB) September 23, 2009 -- Christopher Reeve Day (9/25) has been officially recognized by the ...
... ... MD and Cell Biologist Jose Minguell, PhD,s adult stem cell human clinical ... Stem Cell Summit in Baltimore, MD. All of the trial patients ... diabetic patients reported pain from diabetic neuropathy has ceased. TCA Cellular ...
Cached Medicine News:Health News:Study reveals 2/3 of prostate cancer patients do not need treatment 2Health News:One Shot May Someday Replace Six for Rabies 2Health News:University of Hawaii-Maui Community College Selects American TeleCare for Allied Health Department's Nursing Telehealth Project 2Health News:University of Hawaii-Maui Community College Selects American TeleCare for Allied Health Department's Nursing Telehealth Project 3Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 2Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 3Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 4Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 5Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 6Health News:First-Ever Christopher Reeve Day (9/25/09) to be Celebrated with Memorable Chicago Events 2Health News:Louisiana's TCA Cellular Therapy's Findings Reported at World Stem Cell Summit -- Patients' Legs Saved from Amputation Using Adult Stem Cells 2Health News:Louisiana's TCA Cellular Therapy's Findings Reported at World Stem Cell Summit -- Patients' Legs Saved from Amputation Using Adult Stem Cells 3
... The Zeus Scientific, Inc. ENA Profile-6 ... for the detection of IgG antibodies to ... in human sera. When performed according to ... autoantibody profile may aid in the diagnosis ...
Inquire...
... K-ASSAY Microalbumin Urine Controls are ... use liquid requiring no reconstitution ... from human urine, fortified to ... and creatinine. Preservatives including sodium ...
The K-ASSAY ITA Lyophilized Multi-Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assays for the li...
Medicine Products: